Ishita Drugs & Indus Share Price Today | Stock Price & Ishita Drugs & Indus Share Screener
As of October 5, 2026, the live Ishita Drugs & Indus share price (BSE: ISHITADR) is ₹79.83, up 4.76% from the previous close, with shares trading between ₹75.00 and ₹79.85 in today's trading session, and a 52-week range of ₹67.60–₹83.57. Check ISHITADR 52-week performance for the annual price range and momentum. Use the Ishita Drugs & Indus stock screener below to analyse P/E ratio, market cap, quarterly results, and more. See at what price today Ishita Drugs & Indus opened, then compare its market price and price volume with top gainers and top losers on the exchange. Record your trades in TickJournal's free trading journal and track your portfolio performance.
Key Statistics and Valuation Ratios
Over the trailing twelve months the company reported revenue of ₹13 and net income of ₹1, with EBITDA of ₹1, an operating margin of 6.0% and a profit margin of 7.7%.
Ishita Drugs & Indus Share Price Chart
Track the current stock price of Ishita Drugs & Indus with an interactive chart. Analyse ISHITADR share price trends, closing price, trading volume, historical performance, and volatility using live market data across different timeframes, from the last 30 days to the full record — the complete Ishita Drugs & Indus stock quote in one place.
The quote of ₹79.83 sits between the 52-week low of ₹67.60 and the 52-week high of ₹83.57, and the latest session moved 4.76% from the previous close.
Ishita Drugs & Indus Company Profile - Fundamental Screener
Screen Ishita Drugs & Indus company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for ISHITADR shares across the equity market and its stock price history, plus the wider market trend.
The company is classified under the Healthcare sector and the Pharmaceuticals industry, and it trades under ISIN INE806D01016.
Company Details
Classification
Identifiers and Leadership
Ishita Drugs & Indus Balance Sheet Screener
Screen ISHITADR balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics, then compare equity shares and the debt-to-equity rate against peers in the stock market.
For 2026, total assets were ₹13, down from ₹16 in 2025.
Latest statistics put total assets at ₹13 and shareholder funds at ₹12, with a leverage ratio of 0.18.
| Item | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
Assets |
||||||||||
| Total Assets | 13 | 16 | 11 | 11 | 11 | 9 | 10 | 8 | 7 | 7 |
| Current Assets | 10 | 15 | 10 | 10 | 10 | 8 | 8 | 7 | 6 | 6 |
| Fixed Assets | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
Liabilities |
||||||||||
| Total Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Shareholders' Equity |
||||||||||
| Total Equity | 12 | 11 | 10 | 9 | 9 | 8 | 7 | 6 | 6 | 6 |
| Share Capital | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 |
| Reserves & Surplus | 9 | 8 | 7 | 6 | 6 | 5 | 4 | 3 | 3 | 3 |
Ishita Drugs & Indus Income Statement Screener - Profit & Revenue Analysis
Screen Ishita Drugs & Indus income statement and profit fundamentals. Analyze ISHITADR quarterly results. Ishita Drugs & Indus reports revenue growth, EBITDA, net profit margins, and EPS, and TickJournal's fundamental screener helps with stock evaluation and equity returns.
For None-None, revenue was ₹13 and net profit was ₹1, equal to earnings per unit of ₹2.40, at an operating margin of 6%.
In that period expenses were ₹12, interest cost ₹0 and tax ₹0. The next period listed, 2026-March, shows revenue of ₹15 and net profit of ₹1.
| Item | None-None | 2026-March | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March | 2015-March |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue and Expenses | |||||||||||||
| Revenue | 13 | 15 | 15 | 16 | 12 | 14 | 14 | 15 | 9 | 7 | 7 | 7 | 8 |
| Expenses | 12 | 14 | 14 | 14 | 11 | 13 | 13 | 14 | 9 | 6 | 6 | 7 | 7 |
Operating Costs and Margins | |||||||||||||
| EBITDA | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 1 |
| Operating Profit % | 6.00% | 5.00% | 7.00% | 6.00% | 6.00% | 8.00% | 7.00% | 5.00% | 6.00% | 7.00% | 6.00% | 4.00% | 4.00% |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Profit and Earnings | |||||||||||||
| Profit Before Tax | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 |
| Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Profit | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 |
| EPS | 2.40 | 2.60 | 2.90 | 2.50 | 1.93 | 2.69 | 2.77 | 1.83 | 1.18 | 0.83 | 0.61 | 0.46 | 0.74 |
Ishita Drugs & Indus Cash Flow Screener - Liquidity Fundamentals
Screen ISHITADR cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength and price trend assessment against the wider stock market and other stocks.
In 2026-March, operating activities generated ₹4, and net cash flow was an outflow of ₹2.
Over the same period, investing activities used ₹2 and financing activities used ₹4.
| Item | 2026-March | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations and Investing | ||||||||||
| Operating Activities | 4 | -4 | 2 | -3 | 3 | -1 | 1 | 1 | 1 | 1 |
| Investing Activities | -2 | -1 | 0 | 1 | -1 | 3 | -1 | -1 | -1 | -1 |
Financing and Net Cash | ||||||||||
| Financing Activities | -4 | 4 | -1 | 1 | 0 | 0 | 0 | 0 | 0 | -1 |
| Net Cash Flow | -2 | 0 | 1 | -1 | 2 | 2 | 0 | 0 | 0 | -1 |
Ishita Drugs & Indus Shareholding Pattern Screener
See Ishita Drugs & Indus shareholding pattern with promoter, FII, and DII holdings. Check Ishita Drugs & Indus promoter holding and ownership changes for ISHITADR on TickJournal, and see how institutional stock price moves affect the market.
In 2026-Mar, promoters held 50.04%, foreign institutions 0.00%, domestic institutions 0.00% and the public 47.37%, spread across 5,194 shareholders.
The shareholder count was 5,194 in 2026-Mar, compared with 5,146 in 2026-Jun.
| Item | 2026-Mar | 2026-Jun | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Mar | 2024-Jun |
|---|---|---|---|---|---|---|---|---|
Promoter Holding | ||||||||
| Promoter Holding | 50.04% | 50.04% | 49.91% | 49.92% | 49.96% | 50.04% | 49.42% | 49.80% |
Institutional Investors | ||||||||
| FII Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| DII Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Government, Public and Others | ||||||||
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 47.37% | 47.89% | 46.89% | 46.76% | 46.63% | 46.33% | 47.48% | 47.51% |
| Other Holding | 2.60% | 2.07% | 3.20% | 3.33% | 3.42% | 3.63% | 3.09% | 2.69% |
| Shareholder Count | 5,194 | 5,146 | 5,398 | 5,341 | 5,320 | 5,263 | 5,351 | 5,272 |
Dividend Yield Screener - Share Price & Share Analysis
Check the dividend history with payout and yield data. View dividend details including ex-dates, the dividend rate, and amounts paid by Ishita Drugs & Indus. Ishita Drugs & Indus dividend yield can be compared with peers and other stocks in the market.
Ishita Drugs & Indus Stock Index Membership - Nifty & Sensex
See which indices include Ishita Drugs & Indus stock. Check ISHITADR index membership in NIFTY 50, SENSEX, and other indices on TickJournal, and compare the Nifty trend with the broader market trend.
Complete Index List
Ishita Drugs & Indus Market Events Screener - Corporate Actions
Get Ishita Drugs & Indus corporate actions including splits, bonuses, and buybacks disclosed to the exchange. Check Ishita Drugs & Indus stock events that may affect ISHITADR share price, along with derivatives, futures and options activity and sector gainers.
11 corporate actions are listed, the most recent entry being Annual General Meeting dated September 30, 2026, with a record date of September 30, 2026.
It is followed by Quarterly Result Announcement dated August 8, 2026 and Quarterly Result Announcement dated May 30, 2026.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| 2026-09-30 | 2026-09-30 | Annual General Meeting | NA | -0.28% |
| 2026-08-08 | 2026-08-08 | Quarterly Result Announcement | NA | -1.20% |
| 2026-05-30 | 2026-05-30 | Quarterly Result Announcement | NA | -2.87% |
| 2026-02-07 | 2026-02-07 | Quarterly Result Announcement | NA | 6.73% |
| 2025-11-11 | 2025-11-11 | Quarterly Result Announcement | NA | -0.40% |
| 2025-09-29 | 2025-09-29 | Annual General Meeting | NA | 8.66% |
| 2025-08-12 | 2025-08-12 | Quarterly Result Announcement | NA | -9.29% |
| 2025-05-30 | 2025-05-30 | Quarterly Result Announcement | NA | -2.94% |
| 2025-02-13 | 2025-02-13 | Quarterly Result Announcement | NA | -12.35% |
| 2024-11-12 | 2024-11-12 | Quarterly Result Announcement | NA | 1.31% |
| 2024-09-30 | 2024-09-30 | Annual General Meeting | NA | -3.22% |
Ishita Drugs & Indus Competitors Screener - Peer Stocks Comparison
Screen ISHITADR competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance, from valuation and price target to the future price outlook, for better stock selection in a changing stock market.
The comparison table covers 10 companies in the Healthcare sector, shown with market capitalisation, P/E ratio, revenue, growth, net profit and RSI.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 432,120 | 36.04 | 61,674 | 12.69% | 11,565 | 36.68 |
| Divis Laboratories | 245,532 | 84.24 | 11,067 | 13.95% | 2,568 | 51.70 |
| Torrent Pharmaceuticals | 181,333 | 84.71 | 13,886 | 20.34% | 2,138 | 41.12 |
| Zydus Life Science | 114,284 | 25.27 | 27,658 | 17.64% | 5,026 | 47.64 |
| Cipla | 108,576 | 32.50 | 29,045 | 2.24% | 3,870 | 34.78 |
| Laurus Labs | 107,198 | 98.20 | 6,868 | 22.01% | 890 | 58.70 |
| Mankind Pharma | 104,707 | 50.04 | 14,636 | 14.85% | 1,938 | 61.75 |
| Dr Reddys Laboratories | 100,679 | 32.41 | 35,059 | 3.90% | 4,158 | 53.84 |
| Aurobindo Pharma | 96,479 | 25.84 | 34,145 | 5.56% | 3,503 | 50.30 |
| Lupin | 92,885 | 16.82 | 29,039 | 26.75% | 5,356 | 31.59 |
Ishita Drugs & Indus Company Announcements - News & Reports Screener
Screen ISHITADR latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis, and review the option chain for related stocks. Compare other stocks in the same sector.
20 recent announcements are listed, the latest dated October 3, 2026.
The next most recent announcements are dated October 3, 2026 and October 3, 2026.
| Date | Update | Actions |
|---|---|---|
| 2026-10-03 | Announcement under Regulation 30 (LODR)-Change in Management | - |
| 2026-10-03 | Announcement under Regulation 30 (LODR)-Appointment of Statutory Auditor/s | - |
| 2026-10-03 | Shareholder Meeting / Postal Ballot-Scrutinizers Report | - |
| 2026-10-01 | Shareholder Meeting / Postal Ballot-Outcome of AGM | - |
| 2026-09-27 | Closure of Trading Window | - |
| 2026-09-22 | Disclosure Under Regulation 30 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015 - Availing Credit Facilities From Bank | - |
| 2026-09-22 | Board Meeting Outcome for Outcome Of Board Meeting Held On 22Nd September 2026 | - |
| 2026-09-18 | Board Meeting Intimation for Intimation Of Board Meeting Pursuant To Regulation 29 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 | - |
| 2026-08-31 | Weblink Intimation Letter To The Shareholders | - |
| 2026-08-27 | Reg. 34 (1) Annual Report. | - |
| 2026-08-27 | NOTICE OF 33RD ANNUAL GENERAL MEETING (AGM) ALONG WITH THE E-VOTING PERIOD | - |
| 2026-08-27 | INTIMATION OF E- VOTING AS PER THE REGULATION 44 OF SEBI (LODR) REGULATION 2015 | - |
| 2026-08-27 | INTIMATION ABOUT THE BOOK CLOSURE FOR 33RD ANNUAL GENERAL MEETING (AGM) | - |
| 2026-08-08 | Announcement under Regulation 30 (LODR)-Change in Management | - |
| 2026-08-08 | Outcome Of Board Meeting Held On 08H August 2026 | - |
| 2026-08-08 | Board Meeting Outcome for Outcome Of Board Meeting Held On 08Th August 2026 | - |
| 2026-07-31 | Board Meeting Intimation for Intimation Of Board Meeting Pursuant To Regulation 29 Of The SEBI (LODR) Regulations 2015 For The Quarter Ended 30Th June 2026. | - |
| 2026-07-09 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | - |
| 2026-06-27 | Closure of Trading Window | - |
| 2026-06-24 | Disclosure Under Regulation 29(2) Of SEBI (Substantial Acquisition Of Shares And Takeovers) Regulations 2011 | - |
Frequently Asked Questions
How is the company valued right now?
The current quote is ₹79.83, within a 52-week range of ₹67.60 to ₹83.57. The P/E ratio is 31.36 and the P/B ratio is 1.91, with earnings per unit of ₹2.60. Market capitalisation stands at ₹22.76 Cr. The company operates in the Healthcare sector, in the Pharmaceuticals industry, so compare these ratios with its sector peers in the table above.
About This Data
Quotes are sourced from the BSE. Key statistics were last updated on October 5, 2026. This page covers 10 balance sheet periods, 13 income statement periods, 10 cash flow years and 8 shareholding periods. Information is provided for research and is not investment advice.